Editing breast cancer tissue with anti-estrogen therapies provides the possibility to enhance pro-apoptotic processes by blocking the frequently occurring up-regulation of cyclin D1 in breast cancer cells with CDK4/6 inhibitors (84). The gene discussed is CCND1; the disease is breast carcinoma.